Skip to main content
. Author manuscript; available in PMC: 2023 Jun 20.
Published in final edited form as: Hypertension. 2013 Nov 15;63(4):878–885. doi: 10.1161/HYP.0000000000000003

Reviewer Disclosures

Reviewer Employment Research Grant Other Research Support Speakers’ Bureau/Honoraria Expert Witness Ownership Interest Consultant/Advisory Board Other
Robert M. Carey University of Virginia Health System NIH None None None None None None
Gregory D. Fink Michigan State University NIH (money paid to institution); AHA (money paid to institution); Medtronic* None None None None None None
John M. Flack Wayne State University NIH*; Novartis*; Medtronic* None Novartis None None Novartis; NIH*; Medtronic*; Back Beat Hypertension*; NIVasc* None
Daniel W. Jones University of Mississippi None None None None None None None
Janet Wright CDC None None None None None None None

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10,000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10,000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

*

Modest.

Significant.